The real-world effectiveness of sucroferric oxyhydroxide in European hemodialysis patients: a 1-year retrospective database analysis.

Rosa Ramos SánchezCharles ChazotAnibal FerreiraAttilio Di BenedettoKonstantin GurevichAstrid FeuersengerMelanie WolfHans-Jürgen ArensSebastian WalpenStefano Stuard

Published in: BMC nephrology (2020)

In this real-world study of European hemodialysis patients, prescription of SFOH as monotherapy to PB-naïve patients, or in addition to existing PB therapy, was associated with significant improvements in serum phosphate control and a low daily pill burden.

Keyphrases

end stage renal disease
heavy metals
ejection fraction
newly diagnosed
randomized controlled trial
chronic kidney disease
prognostic factors
cross sectional
peritoneal dialysis
stem cells
open label
risk assessment
clinical trial
combination therapy
study protocol